Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

CLL Cells From Subjects Treated with Rituximab and Alemtuzumab Can Lose Target Antigen and Develop Resistance to Mab-Mediated Complement Dependent Cytotoxicity

Ronald P Taylor, PhD, Clive S. Zent, MD, Paul V Beum, PhD, Margaret A Lindorfer, PhD, George Weiner, MD

Blood (2010) 116 (21): 3585.

https://doi.org/10.1182/blood.V116.21.3585.3585

Published: 2010

Journal Articles

Rapid Clearance of Rituximab Contributes to the Continued High Incidence of Autoimmune Complications of Chemoimmunotherapy for Chronic Lymphocytic Leukemia

Clifton C. Mo, MD, Mohammed Z.H. Farooqui, DO, Paul V. Beum, PhD, Ndegwa Njuguna, MD, Gerald E Marti, MD, PhD, Wyndham H. Wilson, MD, PhD, Ronald P. Taylor, PhD, Adrian U. Wiestner, MD, PhD

Blood (2010) 116 (21): 4628.

https://doi.org/10.1182/blood.V116.21.4628.4628

Published: 2010

Journal Articles

Examination of the Relative Rates of Rituximab-Mediated Loss of CD20 From B Cells Via Trogocytosis Versus Internalization. Implications for Rituximab Therapy of CLL

Ronald P Taylor, PhD, Paul V Beum, PhD, Margaret A Lindorfer, PhD, Elizabeth M Peek

Blood (2010) 116 (21): 2404.

https://doi.org/10.1182/blood.V116.21.2404.2404

Published: 2010

Journal Articles

High Incidence of Autoimmune Complications during Combined Fludarabine and Rituximab Therapy in CLL: Rapid Clearance of Rituximab as a Contributing Factor

Ndegwa Njuguna, MD, Paul V Beum, PhD, Berengere Vire, PhD, Gerald E Marti, MD, PhD, Therese White, RN, Wyndham H. Wilson, MD, PhD, Ronald P Taylor, PhD, Adrian Wiestner, MD, PhD

Blood (2008) 112 (11): 4208.

https://doi.org/10.1182/blood.V112.11.4208.4208

Published: 2008

Journal Articles

Complement (C) Activation Followed by Penetration of the Membrane Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which Induces Streamers. Generalization of Streaming to Include other Mabs and Target Cells.

Ronald P. Taylor, PhD, Paul V. Beum, PhD, P. Todd Stukenberg, PhD, Andrew W. Pawluczkowycz, MS, Margaret A. Lindorfer, PhD, Frank J. Beurskens, PhD, Paul W. H. I. Parren, PhD, Jan G. J. van de Winkel, PhD

Blood (2008) 112 (11): 1577.

https://doi.org/10.1182/blood.V112.11.1577.1577

Published: 2008

Journal Articles

Spinning Disk Confocal Fluorescent Microscopy (SDCFM) Analyses of Complement Activation Promoted by Anti-CD20 Monoclonal Antibodies (mAbs) Rituximab and Ofatumumab.

Ronald P. Taylor, PhD, Paul V. Beum, PhD, Andrew W. Pawluczkowycz, Ms, Margaret A. Lindorfer, PhD, Frank Beurskens, PhD, Jan van de Winkel, PhD, Paul Parren, PhD

Blood (2007) 110 (11): 2345.

https://doi.org/10.1182/blood.V110.11.2345.2345

Published: 2007

Journal Articles

Complement Activation and Complement-Mediated Killing of B Cells Promoted by Anti-CD20 Monoclonal Antibodies (mAb) Rituximab and Ofatumumab Are Rapid, and Ofatumumab Kills Cells More Rapidly and with Greater Efficacy.

Ronald P. Taylor, PhD, Andrew W. Pawluczkowycz, Ms, Paul V. Beum, PhD, Margaret A. Lindorfer, PhD, Frank Beurskens, PhD, Jan van de Winkel, PhD, Paul Parren, PhD

Blood (2007) 110 (11): 2352.

https://doi.org/10.1182/blood.V110.11.2352.2352

Published: 2007

Journal Articles

The Shaving Reaction Is Facilitated through Trogocytosis: Concerted Transfer of Both Rituximab (RTX) and the Membrane Dye PKH26 from B Lymphocytes to Macrophages Is Demonstrable by Flow Cytometry, Fluorescence Microscopy, and High Resolution Digital Imaging in a Flow Cytometric Environment.

David A. Mack, MD, Paul V. Beum, PhD, Margaret A. Lindorfer, PhD, Andrew W. Pawluczkowycz, MS, Ronald P. Taylor, PhD

Blood (2006) 108 (11): 2096.

https://doi.org/10.1182/blood.V108.11.2096.2096

Published: 2006

Journal Articles

The Shaving Reaction. Rituximab/CD20 Complexes Are Removed from Mantle Cell Lymphoma Cells (Z138) and Chronic Lymphocytic Leukemia (CLL) Cells by Monocyte/Macrophages: In Vitro Studies and a SCID Mouse Model.

Ronald P. Taylor, PhD, Paul V. Beum, PhD, Yongli Li, MD, Margaret A. Lindorfer, PhD, Michael E. Williams, MD

Blood (2005) 106 (11): 2968.

https://doi.org/10.1182/blood.V106.11.2968.2968

Published: 2005

Journal Articles

Pilot Study of Thrice-Weekly Low-Dose Rituximab (RTX) in Chronic Lymphocytic Leukemia (CLL): Decreased CD20 Loss Via “Shaving” and a Novel Strategy for Enhanced Therapeutic Targeting.

Michael E. Williams, MD, John J. Densmore, MD, PhD, Andrew W. Pawluczkowycz, MS, Paul V. Beum, PhD, Adam D. Kennedy, PhD, Margaret A. Lindorfer, PhD, Susan H. Hamil, RN, Gina R. Petroni, PhD, Jane C. Eggleton, RN, Ronald P. Taylor, PhD

Blood (2005) 106 (11): 2970.

https://doi.org/10.1182/blood.V106.11.2970.2970

Published: 2005

NARROW

CLL Cells From Subjects Treated with Rituximab and Alemtuzumab Can Lose Target Antigen and Develop Resistance to Mab-Mediated Complement Dependent Cytotoxicity

Rapid Clearance of Rituximab Contributes to the Continued High Incidence of Autoimmune Complications of Chemoimmunotherapy for Chronic Lymphocytic Leukemia

Examination of the Relative Rates of Rituximab-Mediated Loss of CD20 From B Cells Via Trogocytosis Versus Internalization. Implications for Rituximab Therapy of CLL

High Incidence of Autoimmune Complications during Combined Fludarabine and Rituximab Therapy in CLL: Rapid Clearance of Rituximab as a Contributing Factor

Complement (C) Activation Followed by Penetration of the Membrane Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which Induces Streamers. Generalization of Streaming to Include other Mabs and Target Cells.

Spinning Disk Confocal Fluorescent Microscopy (SDCFM) Analyses of Complement Activation Promoted by Anti-CD20 Monoclonal Antibodies (mAbs) Rituximab and Ofatumumab.

Complement Activation and Complement-Mediated Killing of B Cells Promoted by Anti-CD20 Monoclonal Antibodies (mAb) Rituximab and Ofatumumab Are Rapid, and Ofatumumab Kills Cells More Rapidly and with Greater Efficacy.

The Shaving Reaction Is Facilitated through Trogocytosis: Concerted Transfer of Both Rituximab (RTX) and the Membrane Dye PKH26 from B Lymphocytes to Macrophages Is Demonstrable by Flow Cytometry, Fluorescence Microscopy, and High Resolution Digital Imaging in a Flow Cytometric Environment.

The Shaving Reaction. Rituximab/CD20 Complexes Are Removed from Mantle Cell Lymphoma Cells (Z138) and Chronic Lymphocytic Leukemia (CLL) Cells by Monocyte/Macrophages: In Vitro Studies and a SCID Mouse Model.

Pilot Study of Thrice-Weekly Low-Dose Rituximab (RTX) in Chronic Lymphocytic Leukemia (CLL): Decreased CD20 Loss Via “Shaving” and a Novel Strategy for Enhanced Therapeutic Targeting.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only